AxoGen, Inc. provided revenue guidance for the year 2024. The company maintained its full year guidance with 2024 revenue in the range of $177 million to $181 million, which represents a growth rate of approximately 11% to 14%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.64 USD | +5.90% | +9.03% | -2.78% |
May. 28 | Axogen, Inc. Announces the Opening of its Axogen Processing Center | CI |
May. 16 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.78% | 290M | |
+7.87% | 219B | |
+11.83% | 192B | |
+18.87% | 142B | |
+30.03% | 111B | |
+2.32% | 65.32B | |
+14.15% | 52.45B | |
+2.68% | 49.8B | |
+6.60% | 43.43B | |
+1.85% | 35.95B |
- Stock Market
- Equities
- AXGN Stock
- News AxoGen, Inc.
- Axogen, Inc. Provides Revenue Guidance for the Year 2024